NAV

TAS-117

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
TAS-117
DrugBank Accession Number
DB15054
Background

TAS-117 is under investigation in clinical trial NCT03017521 (K-BASKET, TAS-117, PI3K/AKT Gene Aberration).

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 424.504
Monoisotopic: 424.189926029
Chemical Formula
C26H24N4O2
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
QI52W1ZIIB
CAS number
1402602-94-1
InChI Key
AIFGVDXMHWGOGJ-DIVCQZSQSA-N
InChI
InChI=1S/C26H24N4O2/c1-25(31)14-26(27,15-25)19-9-7-17(8-10-19)22-23(18-5-3-2-4-6-18)30-16-32-21-11-12-28-13-20(21)24(30)29-22/h2-13,31H,14-16,27H2,1H3/t25-,26-
IUPAC Name
(1r,3s)-3-amino-1-methyl-3-(4-{5-phenyl-8-oxa-3,6,12-triazatricyclo[7.4.0.0^{2,6}]trideca-1(13),2,4,9,11-pentaen-4-yl}phenyl)cyclobutan-1-ol
SMILES
C[C@@]1(O)C[C@@](N)(C1)C1=CC=C(C=C1)C1=C(N2COC3=CC=NC=C3C2=N1)C1=CC=CC=C1

References

General References
Not Available
ChemSpider
64854605

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAdult Solid Tumor1
1TerminatedTreatmentAdvanced or Metastatic Solid Tumors Irrespective of Gene Alterations / Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00628 mg/mLALOGPS
logP3.04ALOGPS
logP2.97Chemaxon
logS-4.8ALOGPS
pKa (Strongest Acidic)15.14Chemaxon
pKa (Strongest Basic)9.06Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area86.19 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity132.33 m3·mol-1Chemaxon
Polarizability47.52 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 14:45 / Updated at June 12, 2020 16:53